Payment overview · 2025
General Payments
$94.96
6 reported records · 4 companies
Healthcare provider profile · identity verified
Jonathan David Wilks, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · OKLAHOMA CITY, OK · NPI 1740385533
Verified facts
What the public records show
CMS Open Payments records show Jonathan David Wilks, M.D. received $94.96 in general payments during 2025 across 6 reported records.
Amgen Inc. accounted for 51.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 274 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $48.61 | 51.2% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.15 | 19.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.41 | 15.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.79 | 14.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $94.96 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $48.61 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $48.61 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $18.15 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $14.41 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $13.79 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $13.79 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 274 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
274 | 55 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1035 | 305 |
| Levothyroxine Sodium | Levothyroxine Sodium | 583 | 159 |
| Losartan Potassium | Losartan Potassium | 567 | 165 |
| Amlodipine Besylate | Amlodipine Besylate | 562 | 173 |
| Metformin Hcl | Metformin Hcl | 446 | 121 |
| Lisinopril | Lisinopril | 430 | 123 |
| Metoprolol Succinate | Metoprolol Succinate | 359 | 103 |
| Hydrochlorothiazide | Hydrochlorothiazide | 314 | 91 |
| Eliquis | Apixaban | 274 | 55 |
| Gabapentin | Gabapentin | 270 | 81 |
| Pantoprazole Sodium | Pantoprazole Sodium | 268 | 81 |
| Omeprazole | Omeprazole | 251 | 68 |
| Simvastatin | Simvastatin | 227 | 63 |
| Tamsulosin Hcl | Tamsulosin Hcl | 202 | 72 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 194 | 44 |
| Pravastatin Sodium | Pravastatin Sodium | 192 | 50 |
| Glimepiride | Glimepiride | 181 | 57 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 180 | 60 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 170 | 49 |
| Allopurinol | Allopurinol | 169 | 44 |
| Furosemide | Furosemide | 169 | 51 |
| Carvedilol | Carvedilol | 161 | 48 |
| Trazodone Hcl | Trazodone Hcl | 161 | 39 |
| Sertraline Hcl | Sertraline Hcl | 160 | 61 |
| Alprazolam | Alprazolam | 154 | 37 |
| Pioglitazone Hcl | Pioglitazone Hcl | 153 | 45 |
| Alendronate Sodium | Alendronate Sodium | 139 | 56 |
| Meloxicam | Meloxicam | 139 | 39 |
| Potassium Chloride | Potassium Chloride | 131 | 31 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 130 | 42 |
| Montelukast Sodium | Montelukast Sodium | 127 | 34 |
| Ozempic | Semaglutide | 125 | 28 |
| Finasteride | Finasteride | 124 | 40 |
| Zolpidem Tartrate | Zolpidem Tartrate | 121 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 118 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 115 | 42 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 102 | 29 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 97 | 25 |
| Metformin Hcl Er | Metformin Hcl | 95 | 30 |
| Paroxetine Hcl | Paroxetine Hcl | 95 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 93 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 91 | 26 |
| Famotidine | Famotidine | 91 | 31 |
| Tramadol Hcl | Tramadol Hcl | 88 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 86 | 24 |
| Tizanidine Hcl | Tizanidine Hcl | 77 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 73 | 18 |
| Januvia | Sitagliptin Phosphate | 73 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 71 | 21 |
| Breo Ellipta | Fluticasone/Vilanterol | 67 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 65 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 64 | 19 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 58 | 28 |
| Atenolol | Atenolol | 57 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 57 | 21 |
| Lovastatin | Lovastatin | 53 | 16 |
| Spironolactone | Spironolactone | 51 | 15 |
| Naproxen | Naproxen | 50 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 50 | 20 |
| Clonazepam | Clonazepam | 48 | 11 |
| Synthroid | Levothyroxine Sodium | 47 | suppressed |
| Trulicity | Dulaglutide | 47 | suppressed |
| Pregabalin | Pregabalin | 45 | 17 |
| Celecoxib | Celecoxib | 43 | 18 |
| Jardiance | Empagliflozin | 43 | 13 |
| Benazepril Hcl | Benazepril Hcl | 42 | suppressed |
| Mounjaro | Tirzepatide | 42 | 11 |
| Bupropion Xl | Bupropion Hcl | 40 | 13 |
| Myrbetriq | Mirabegron | 40 | 11 |
| Warfarin Sodium | Warfarin Sodium | 39 | suppressed |
| Torsemide | Torsemide | 38 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 37 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 36 | suppressed |
| Chlorthalidone | Chlorthalidone | 35 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 35 | 12 |
| Clonidine Hcl | Clonidine Hcl | 34 | 12 |
| Lorazepam | Lorazepam | 33 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 31 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | suppressed |
| Levetiracetam | Levetiracetam | 30 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 30 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 29 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 29 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 28 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 28 | 24 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | suppressed |
| Aripiprazole | Aripiprazole | 27 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 27 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 27 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 26 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 26 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 26 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Estradiol | Estradiol | 24 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 23 | suppressed |
| Diazepam | Diazepam | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 23 | 16 |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Ezetimibe | Ezetimibe | 22 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Ibuprofen | Ibuprofen | 22 | suppressed |
| Ramipril | Ramipril | 22 | suppressed |
| Temazepam | Temazepam | 22 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Dutasteride | Dutasteride | 21 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 21 | suppressed |
| Prednisone | Prednisone | 21 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 15 |
| Ketoconazole | Ketoconazole | 20 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 20 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | 14 |
| Acyclovir | Acyclovir | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 19 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Latanoprost | Latanoprost | 18 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Amantadine | Amantadine Hcl | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 15 |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Carbamazepine Er | Carbamazepine | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Nicardipine Hcl | Nicardipine Hcl | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Klor-Con 10 | Potassium Chloride | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 11 | suppressed |
| Lomotil | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $94.96 · 6 records | Amgen Inc. | AREXVY, BREZTRI, ELIQUIS, OTEZLA, REPATHA, SHINGRIX | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error